Stock Price & Analysis

Based on the recent data and analyst perspectives, BDX stock appears to be a hold at current levels due to mixed signals - while Q1 performance was strong with EPS/revenue beats, the company's planned separation of its Biosciences unit and lowered FY25 revenue guidance create some near-term uncertainty.

The stock is currently trading at $230.03 with strong analyst support - Wells Fargo maintains an Overweight rating with a $270 target, while Barclays reiterates Buy with a $278 target, suggesting ~20% upside potential from current levels.

Based on recent analyst reports and technical analysis, BDX stock is projected to reach $273-$278 by end of 2025, supported by strong Q1 2025 performance and planned separation of Biosciences business. The stock currently trades at $230.03 with RSI at 40.65 indicating neutral momentum, while multiple analysts maintain "Strong Buy" ratings with an average target of $273.33, suggesting ~19% upside potential. The successful execution of business separation planned for 2026 and continued operational improvements in core MedTech segments are expected to be key price drivers.

The S1 support level for BDX Stock is $229.32 ,The R1 resistant level for BDX Stock is $250.43.

As of the end of day on 2025-02-10, the price of BDX Stock was $230.

The target price for BDX Stock according to analyst rating is 273.33, with the highest price target at 290.00 and the lowest at 245.00. Analysts have a Strong Buy rating on BDX Stock overall.

The market cap of BDX is $65.9B.

Based on the provided data, here is a comprehensive analysis of BDX's valuation:

Valuation Analysis BDX appears overvalued based on several key metrics. The company's P/E ratio has remained elevated at 38.21 in Q1 2025, which is significantly higher than industry averages. The EV/EBITDA ratio of 15.91 also indicates premium valuation compared to peers in the medical technology sector.

Financial Performance The company's net income has shown a concerning downward trend over recent quarters:

• Q2 2024: $537M
• Q3 2024: $487M
• Q4 2024: $400M
• Q1 2025: $303M

This 43.6% decline in net income over three quarters raises concerns about profitability and operational efficiency.

Recent Developments BDX recently announced plans to separate its Biosciences and Diagnostic Solutions business, which has created some uncertainty around the company's future structure and growth prospects. While this could potentially unlock value, the transition period may present execution risks.

Market Sentiment Recent analyst actions reflect mixed views - Wells Fargo lowered their price target to $270 from $275, while Barclays maintained a Buy rating with a $278 target. However, insider selling activity, with 66 insiders reducing positions, suggests potential concerns from those closest to the business.

Conclusion BDX appears overvalued at current levels due to declining profitability metrics, premium valuation multiples, and uncertain business restructuring outcomes. The consistent pattern of declining earnings coupled with insider selling activity further supports this conclusion.

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Based on the available data and analyst projections, here's the 2030 price prediction for BDX stock:

BDX stock is expected to reach $345-355 by 2030, representing a 50% upside from current levels, driven by the successful execution of its planned separation of Biosciences and Diagnostic Solutions business and strong growth in its core MedTech segments.

The company's recent strategic moves to become a pure-play medical technology company focusing on high-impact R&D and disciplined capital allocation positions it well for sustained long-term growth through 2030.

Current analyst consensus maintains a Strong Buy rating with near-term price targets averaging $273.33, suggesting the stock is well-positioned to achieve the 2030 target through consistent execution and margin expansion.

BDX has a total of 73000 employees.